Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity-Reference-Cited by-同舟云学术

Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity

Published:2023-07 Issue:15 Volume:186 Page:3148-3165.e20
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Ma Leyuan^ORCID,Hostetler Alexander,Morgan Duncan M.,Maiorino Laura,Sulkaj Ina,Whittaker Charles A.,Neeser Alexandra,Pires Ivan Susin,Yousefpour Parisa,Gregory Justin,Qureshi Kashif,Dye Jonathan,Abraham Wuhbet,Suh Heikyung,Li Na,Love J. Christopher,Irvine Darrell J.

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference87 articles.

1. The future of engineered immune cell therapies;Irvine;Science,2022

2. CAR immune cells: design principles, resistance and the next generation;Labanieh;Nature,2023

3. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma;Wang;N. Engl. J. Med.,2020

4. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia;Maude;N. Engl. J. Med.,2018

5. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (Transcend NHL 001): a multicentre seamless design study;Abramson;Lancet,2020

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Therapeutic Approaches Targeting Ferroptosis in Cancer: Focus on Immunotherapy and Nanotechnology;Current Pharmaceutical Biotechnology;2024-11

2. Self-assembly nanoparticles potentiate in-situ tumor vaccine of radiotherapy by regulating tumor immunogenicity and tumor-associated macrophages;Chemical Engineering Journal;2024-10

3. Effect of structural features on the antitumor activity of plant and microbial polysaccharides: A review;Food Bioscience;2024-10

4. Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors;Expert Opinion on Biological Therapy;2024-09-02

5. TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models;Molecular Therapy: Oncology;2024-09